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Abstract
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Protein tyrosine phosphorylation is a crucial signaling mechanism that plays a role in epithelial
carcinogenesis. Protein tyrosine kinases (PTKs) control various cellular processes including
growth, differentiation, metabolism, and motility by activating major signaling pathways including
STAT3, AKT, and MAPK. Genetic mutation of PTKs and/or prolonged activation of PTKs and
their downstream pathways can lead to the development of epithelial cancer. Therefore, PTKs
became an attractive target for cancer prevention. PTK inhibitors are continuously being
developed, and they are currently used for the treatment of cancers that show a high expression of
PTKs. Protein tyrosine phosphatases (PTPs), the homeostatic counterpart of PTKs, negatively
regulate the rate and duration of phosphotyrosine signaling. PTPs initially were considered to be
only housekeeping enzymes with low specificity. However, recent studies have demonstrated that
PTPs can function as either tumor suppressors or tumor promoters, depending on their target
substrates. Together, both PTK and PTP signal transduction pathways are potential therapeutic
targets for cancer prevention and treatment.
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INTRODUCTION
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Protein phosphorylation is a post-translational modification that regulates protein function in
response to exogenous factors. Phosphorylation of substrate proteins on serine, threonine, or
tyrosine residues by protein kinases modulates diverse physiological functions. While more
than 95% of protein phosphorylation occurs on serine or threonine residues, tyrosine
phosphorylation only makes up less than 1% of total cellular phosphorylation. Even though
its contribution to total phosphorylation is very small compared with serine or threonine
phosphorylation, tyrosine phosphorylation is still a critical signaling mechanism needed to
maintain cellular function and homeostasis, and abnormal phosphotyrosine signaling can
facilitate the development of cancer [1,2].
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Approximately 35 years ago, protein tyrosine kinases (PTKs), enzymes that catalyze
tyrosine phosphorylation of specific target proteins, were identified. Since that time 90 genes
that encode PTKs have been discovered in the human genome. Among them, 58 PTKs are
receptor type kinases and 32 PTKs are non-receptor type kinases, located in the cytoplasm
[1–3]. Both the activation of receptor type PTKs through the binding of ligands such as
growth factor receptors, and the activation of non-receptor type PTKs modulate major
cellular processes including cell proliferation, apoptosis, angiogenesis, and cell motility via
signal transduction. Aberrant PTK signaling has been implicated in various types of cancers,
with the observation that 51 of 90 PTKs are associated with cancer through mutation or
overexpression [4–6]. As a result, PTKs have been studied extensively in order to develop
PTK inhibitors for the prevention and treatment of cancer. Subsequently, several PTK
inhibitors have been developed by pharmaceutical companies and approved for medical use
by the FDA [7–9].
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Besides exogenous regulation by inhibitors, PTK activity is endogenously regulated by
negative feedback mechanisms. Protein tyrosine phosphatases (PTPs) can be activated to
directly dephosphorylate target proteins and thereby negatively regulate phosphotyrosine
signaling [10–12]. PTPs were first identified in the late 1980s by Nicholas Tonks and
colleagues, approximately 10 years after the discovery of PTKs [13]. Since then, studies
using the conserved catalytic domain of PTPs to search the human genome database have
identified at least 107 PTPs encoded in the human genome [14,15]. PTPs are classified into
four groups based on the amino acid sequences of their catalytic domains. The largest group,
the class I cysteine-based PTPs, consists of 99 PTPs, including 38 well-known classical
PTPs that have strict specificity for phosphotyrosine. These classical PTPs are further
categorized as either receptor-like PTPs or nonreceptor-like PTPs [16–19]. Importantly,
functional studies have demonstrated that PTPs are associated with carcinogenesis similar to
PTKs. Of the 38 classical PTPs, 22 have been shown to play a tumor suppressive role in
different types of human cancer. These tumor suppressive PTPs include eleven members of
the receptor-like PTP subfamily (PTPRA, PTPRD, PTPRF, PTPRG, PTPRH, PTPRJ,
PTPRK, PTPRM, PTPRO, PTPRS, and PTPRT) and eleven members of the nonreceptor-like
PTP subfamily (PTP1B, TC-PTP, PTPH1, STEP, SHP1, HePTP, PTP-PEST, PTPBAS,
PTP36, BDP, and PTPD1). Given this tumor suppressive capability, it is reasonable to
hypothesize that cancer cells may bear somatic mutations of PTPs and/or underexpress PTPs
[15]. On the other hand, other PTPs have been shown to act as oncogenes by stimulating cell
proliferation and survival. Studies have identified 11 of the 38 classical PTPs act as potential
oncogenes [15,20,21]. These oncogenic PTPs include five members of the receptor-like PTP
subfamily (PTPRA, PTPRB, PTPRF, PTPRG, and PTPRH) and six members of the
nonreceptor-like PTP subfamily (PTP1B, PTPH1, SHP1, HePTP, SHP2, and PTPD1). In
order to combat the oncogenic functions of some PTPs, inhibitors were developed to use as
potent anti-tumor drugs.
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PTK IN CARCINOGENESIS
The roles of PTKs in cell signaling
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Protein tyrosine kinases (PTKs) are essential enzymes which can transfer a phosphate to the
amino acid tyrosine within a protein [22]. Phosphorylation of tyrosine residues by PTKs
changes the properties of a protein so that it becomes active and transmits the cellular signal
downstream in a cascading manner [23]. The activation of PTKs is involved in various major
cellular processes including cell growth, differentiation, cytoskeletal rearrangement, cell
migration, and apoptosis [4]. These PTK–mediated signaling pathways are regulated by
protein tyrosine phosphatase (PTPs). Until now, approximately 20 receptor tyrosine kinase
(RTK) families and at least 10 distinct groups of non-receptor tyrosine kinases have been
identified in humans and represent about 2% of all human genes [3]. Most RTKs are singlepass, transmembrane proteins. Upon binding of a ligand like epithelial growth factor (EGF),
RTKs promote their dimerization and the subsequent autophosphorylation of receptor
tyrosine residues transmits extracellular signals to the cytoplasm or to the nucleus (Figure 1).
Non-receptor tyrosine kinase is localized in the cytosol or nuclear matrix [24]. Interestingly,
those kinases found in the nuclear envelope may be involved in DNA stability, mitosis, or
DNA repair [25]. The signals transmitted by RTKs to the nucleus may modify gene
expression by activating transcriptional factors or by regulating cell cycle-associated
proteins. Therefore, mutation of PTKs which permit aberrant expression and constitutive
activation of PTKs, initiates and promotes carcinogenesis [26].
PTK in skin carcinogenesis
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Since the discovery of the association between multistage carcinogens and Harvey-ras gene
in 1983 [27], the mouse skin model of multistage carcinogenesis has been a relatively
simple, well-designed, and useful tool, providing evidence on how accumulated genetic
change can lead to tumorigenesis and providing clues towards the development of
therapeutic methods to prevent carcinogenesis [28]. In this model for mouse skin
carcinogenesis, skin tumor development occurs via three major stages - initiation, promotion
and progression [29]. Tumor initiation by a single topical subcarcinogenic dose of the
genotoxic carcinogen, such as 7, 12-dimethylbenz[α]anthrancene (DMBA), induces a
mutation in a critical gene (Ha-ras) or genes. Typically, this initiation stage does not produce
morphological changes in mouse skin. Following initiation, tumor promotion occurs by
repeatedly applying the non-mutagenic tumor promoter, such as 12-Otetradecanoylphorbol-13-acetate (TPA), triggering a variety of tumor-related gene expression
which affects epidermal cell proliferation and hyperplasia. Cells undergo clonal expansion,
resulting in the development of premalignant papilloma. During this process, many kinases
and phosphatases, such as RTKs and PTPs, are activated by posttranslational modification.
For example, investigation of the potential regulatory role of epidermal growth factor
receptor (EGFR) in the activity of signal transducer and activator of transcription 3 (STAT3)
during tumor promotion revealed that addition of exogenous EGF in primary cultures of
mouse keratinocytes led to activation of STAT3 as evidenced by an elevation in tyrosine
phosphorylation and nuclear translocation. Also, in the epidermis of transgenic mice
expressing TGFα under control of the keratin 14 promoter, STAT3 was constitutively
activated. However, abrogation of EGFR function in mouse epidermis using an EGFR kinase
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inhibitor or by overexpressing a dominant negative form of EGFR led to a reduction in
STAT3 activation in response to TPA treatment which activates STAT1, 3 and 5 under
normal conditions. Immunoprecipitation analyses using lysates from TPA-treated epidermis
and skin papillomas showed enhanced interaction between EGFR and STAT3. Furthermore,
STAT3 deficiency in mouse epidermis significantly reduced the proliferative response after
TPA treatment. These results revealed STAT3 activation by EGFR in tumor promoter-treated
epidermis and in skin papillomas may be a critical event during mouse skin tumor
promotion, possibly through regulation of keratinocyte proliferation [30,31]. In the final
stage of multistage mouse skin carcinogenesis, progression, papillomas convert to squamous
carcinoma in correlation with additional epigenetic modulation such as gene addition,
deletion or chromosomal switch [29]. Research of skin carcinogenesis has contributed a
great deal to understanding how PTKs can play a role in cancer.
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PTK as a therapeutic target for chemotherapy
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Over half of the 90 PTK genes that have been identified have been shown to be involved in
human cancer either as tumor promoters through gain of function mutations (Bcr-Abl); gene
amplification (EGFR); or overexpression (c-Src) or as tumor suppressors (Syk, c-Fes, Csk,
EphB2, 3 or 4). Since the mid-2000s when gene target therapy began, PTKs have emerged
as validated targets for novel anti-cancer drugs (Figure 2). Recently, inhibitors for EGFR
(afatinib [32], gefitinib [33], erlotinib [34,35], cetuximab [36,37], panitumumab [38],
necitumumab [39], and osimertinib [40]), inhibitors for anaplastic lymphoma kinase (ALK)
(alectinib [41,42], crizotinib [43], brigatinib [44], and ceritinib [45,46]), inhibitors for RET
(cabozantinib [47,48] or and vandetanib [49]) (Table 1), inhibitors for insulin-like growth
factor 1 receptor (IGF-1R) (Cixutumumab [50,51], figitumumab [52], Dalotuzumab [53,54],
Ganitumab [55,56], R1507 [57], Robatumumab [58], AVE1642 [59,60], MEDI-573 [61,62],
Linsitinib [63], BMS-754807 [64,65], and BVP-51004 [66]) (Table 2 and 3), and inhibitors
for Src (Dasatinib [67–72], Saracatinib [73], and Bosutinib [74–78]) (Table 4) have been in
clinical trials for the treatment of a variety of cancers. In this current review, we summarize
the signaling mechanisms and target therapy for representative PTKs including EGFR,
IGF-1R and proto-oncogene c-Src (Src).
EGFR

Author Manuscript

The epidermal growth factor receptor (EGFR; ErbB-1; HER1 in humans) was the first
structure discovered as a receptor tyrosine kinase of the EGF family and it is a member of
the ErbB family of receptors which includes EGFR (ErbB-1), HER2/c-neu (ErbB-2), Her 3
(ErbB-3) and Her 4 (ErbB-4) [79]. Upon binding with its ligands, such as EGF or TGFα,
EGFR can transform to an active homodimer and autophosphorylate [80,81]. In addition,
EGFR may create an active heterodimer with another member of the ErbB receptor family,
such as ErbB2/Her2/neu. Dimerization of EGFR subsequently leads to the
autophosphorylation of several tyrosine (Tyr) residues in the C-terminal domain including
Tyr992, Tyr1045, Tyr1068, Tyr1148 and Tyr1173 [82]. Consequently, autophosphorylated
EGFR can transmit extracellular signals to downstream signaling proteins through several
signal transduction cascades, like the Mitogen-activated protein kinase (MAPK), AKT, Src,
and Janus kinase (JAK) pathways, which leads to DNA synthesis and cell proliferation, cell
survival, cell migration and focal adhesion (Figure 3). Thus, overexpression or aberrant
Curr Pharm Des. Author manuscript; available in PMC 2019 September 16.
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activity of EGFR can contribute to the development of several cancers, including lung
cancer, head and neck carcinoma, and glioblastoma [83–85]. For example, in skin cancer
arising from exposure to ultraviolet B radiation (UVB), UVB has been known to activate
EGFR and induce EGFR-mediated pathways, such as AKT-, PKC-, and protein kinase Adependent signal transduction pathways [86,87]. Additionally, low dose UVB irradiation of
cancer cells overexpressing EGFR prior to adding EGF halted the EGFR signaling pathway
due to conformational change of EGFR by UVB [88,89].

Author Manuscript

Since the identification of EGFR as an oncogene, a variety of therapeutic approaches have
been developed and clinical trials investigating cancer treatments have been performed with
EGFR inhibitors, including gefitinib, erlotinib, and, afatinib for lung cancer, and cetuximab
for lung cancer or colon cancer as shown in Table 1. Generally, monoclonal antibody
inhibitors are divided into two groups by the route, or method of treatment: –MAB is for
intravenous injection (IV) and –IB is for oral drug. With the binding site blocked by a
monoclonal antibody, extracellular signaling molecules can no longer attach and activate the
tyrosine kinase as shown in Figure 1. Another therapeutic approach that targets EGFR is
using small molecules called tyrosine kinase inhibitors, such as gefitinib, brigatinib and
lapatinib, to inhibit the EGFR tyrosine kinase, which is on the cytoplasmic side of the
receptor [90].
In addition, given the issue of drug resistance, other new approaches aimed at EGFR have
been developed. Two sources of resistance, T790M and MET oncogene have been found.
While in clinical trial phase II, brigatinib received breakthrough therapy designation status
by the FDA in October 2014 and is on track to file for approval in the U.S. in the third
quarter of 2016 [44,91].
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IGF-1R
Insulin-like growth factor 1 (IGF-1) is secreted primarily by the liver upon stimulation with
human growth hormone (HGH), whereas IGF-2 is non-HGH dependent and is expressed in a
variety of tissues [92,93]. At least six well-characterized IGF-binding proteins (IGFBP-1
through-6) bind IGFs and prevent their action on the receptors. In serum, only
approximately 2% of IGF ligands exist in the unbound form. At the tissue level,
bioavailability of IGF-1 and IGF-2 is modulated by IGFBP protease and the presence of the
non-signaling, IGF-2-binding IGF-2R [94,95]. IGF-1 binds to at least two receptor tyrosine
kinases, including the IGF-1 receptor (IGF-1R) and the insulin receptor, which transmits
cellular signals by causing the addition of a phosphate molecule on tyrosine residues.
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IGF-1R is a transmembrane receptor that is activated by the IGF-1 hormone and by the
related hormone IGF-2. It belongs to the large class of tyrosine kinase receptors and it is a
member of a family which consists of the insulin receptor (60% homology with IGF-1R)
and the IGF-2R. IGF-1 receptor is comprised of two alpha subunits and two beta subunits.
Both α and β subunits are synthesized from a single mRNA precursor. The precursor is then
glycosylated, cleaved, and crosslinked by cysteine bonds to form a functional
transmembrane αβ chain. The α chains are located at the extracellular membrane, while the
β subunit spans the membrane and is responsible for intracellular signal transduction upon
ligand stimulation. Like EGFR, IGF-1 binding to IGF-1R induces autophosphorylation on
Curr Pharm Des. Author manuscript; available in PMC 2019 September 16.
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tyrosine residues 1165 and 1166 of the receptor and triggers IR substrates (IRS-1 through
−4) and the Src-homology collagen protein (Shc)-mediated cascade signaling pathway
[96,97]. In turn, the Shc-mediated cascade leads to activation of the MAPK pathway and the
phosphatidylinositol-4,5-biphosphate 3-kinase (PI3K)-AKT pathway. These events promote
cell survival and cell proliferation in mitosis-competent cells and in tissues such as skeletal
muscle and cardiac muscle [98,99]. In a recent study using a mouse model lacking the IGF-1
receptor, the loss of IGF-1 resulted in the failure of late development and a dramatic
reduction in body mass [100,101]. Furthermore, aberrant IGF signaling has been shown to
be associated with numerous cancers, including colon cancer [102], prostate cancer [103],
pancreatic cancer [104], melanoma [105], and osteosarcoma [106], as well as childhood
malignancies [107]. For example, increased levels of the IGF-IR are expressed in the
majority of primary and metastatic prostate cancer patient tumors and required for survival
and growth when prostate cancer cells progress to androgen independence [103]. However,
unlike other growth factor receptors such as EGFR and HER-2, activating mutations of the
IGF-1R gene have not been reported.
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Based on the previous successful approach to inhibitors directed against the EGFR family
members, more than 10 IGF/IGF-1R inhibitors have entered clinical trials to test the effect in
the treatment of cancer patients, and these divided into three group: (1) monoclonal
antibodies against IGF-1R, (2) monoclonal antibodies against IGF-1R ligands (IGF-1 and
IGF-2), and (3) IGF-1R tyrosine kinase inhibitors. As shown in Table 2, among IGFR
monoclonal antibodies [50–62], MEDI-573 is the only monoclonal antibody in clinical
development that targets the ligands IGF-1 and IGF-2 [61,62]. MEDI-573 inhibits IGFinduced IGF-1R and IR-activation without inhibiting insulin signaling. Several small
molecule inhibitors against IGF-1R are under clinical investigation [63–66] (Table 3).
Among them, OSI-906 is the most specific, whereas others also inhibit receptor tyrosine
kinases beyond the IGF-1R and IR family because of the high degree of homology between
IGF-1R and IR. Currently, OSI-906 is being tested in combination with erlotinib on patients
with non-small-cell lung carcinoma (NSCLC) possessing EGFR activating mutation; in
combination with standard of care for pancreatic cancer; and combination with cetuximab
for head and neck cancer (https://clinicaltrials.gov). However, thus far, none have shown a
significant benefit. The reason for this failure seems to be the complexity of the IGF-1R
signaling pathway, such as the crosstalk among EGFR, IGF-1R, the estrogen receptor, and
HER-2 which may induce resistance to a drug, as well as a lack of tumor selection markers.
The development of chemoresistance is also an issue which seems to be supported by the
recent data – trastuzumab-resistant ovarian cancer by IGF-1R and ErbB3/HER3 [108] or
centuximab-resistant metastatic colorectal cancer by IGF-1R and c-met [109]. Consequently,
understanding the complexity of the IGF-1R system may be a breakthrough to develop new
therapeutic strategies and approaches including combinational target therapy.
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Src
Proto-oncogene tyrosine-protein kinase Src, known as cellular Src kinase (c-Src), is a nonreceptor tyrosine kinase protein in normal mammalian cells discovered in 1979 [110]. Src
belongs to the Src family of kinases (SFKs) including blk, c-fgr, fyn, hck, lck, lyn, c-Src, cyes, and yrk [111,112]. The constitutive activation of c-Src tyrosine kinase caused by genetic
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mutations is implicated in cancer progression given that c-Src activity promotes signaling by
RTKs like EGFR, HER2, platelet-derived growth factor receptor, IGF-1R and c-Met/
hepatocyte growth factor receptor and c-Src directly transduces survival signals to the
downstream PI3K-AKT and STAT3 pathways [113,114]. Src activation also stabilizes the
focal adhesion complex, which is composed of FAK, paxillin, RhoA and other components
and which stimulates cell adhesion to the extracellular matrix [115,116]. The structure of cSrc consists of six functional regions including an SH4 domain, a unique region, an SH3
domain, an SH2 domain, a tyrosine kinase domain (catalytic domain) and a short regulatory
tail. When Src is inactive, the phosphorylated tyrosine group at the 527 position interacts
with the SH2 domain which helps the SH3 domain interact with the flexible linker domain
and thereby keeps the inactive unit tightly bound. The activation of c-Src causes the
dephosphorylation of the Tyr527 residue and autophosphorylation of the residue Tyr416
[117]. c-Src can be activated by a variety of transmembrane proteins including adhesion
receptors, receptor tyrosine kinases (EGFR), G-protein coupled receptors and cytokine
receptors. Src activation promotes survival, angiogenesis, proliferation and motility. Its
kinase activity can be inhibited via phosphorylation by C-terminal Src kinase which
phosphorylates tyrosine residues located in the C-terminal end of SFKs [118]. The
expression of SFKs depends on tissue and cell types [119–121]. Thus, the aberrant
expression or activation of c-Src in tissue indicates that it is involved in cancer progression.
For example, in colon cancer, increased c-Src expression promotes tumor progression
including metastasis [122,123]. In breast cancer, EGFR not only activates c-Src but also
increases the activity of c-Src. In addition, overexpression of c-Src increases the response of
EGFR-mediated processes, and EGFR and c-Src enhance the effects of one another in
metastatic breast cancer [124,125].
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A number of tyrosine kinase inhibitors of c-Src tyrosine kinase have been developed and
utilized for targeted anti-cancer therapy as shown in Table 4 [67–78]. Among them,
dasatinib (BMS-354825, Sprycel) is a multi-targeted inhibitor of RTKs, including BCRABL fusion protein, stem cell factor receptor, and platelet-derived growth factor receptor,
which led to its approval for the treatment of chronic myeloid leukemia and Philadelphia
chromosome-positive acute lymphocytic leukemia. Dasatinib is also in clinical trials for use
in treating gastrointestinal stromal tumors [126], malignant pleural mesothelioma [126],
sarcomas [127], NSCLC [128], colorectal cancer [129,130], glioblastoma [131], multiple
myeloma [126], melanoma [132,133], head and neck cancer [72], metastatic breast cancer
[134], and prostate cancer [126]. However, recent studies of ongoing combination therapy
with drugs such as erlotinib, FOLFOX and cetuximab reveal the various, complicated roles
of Src signaling.
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IMPORTANT FACTORS INVOLVED IN SIGNALING PATHWAYS REGULATED
BY PTK ACTIVATION
STAT3
Signal transducer and activator of transcription (STAT) proteins were characterized as a
family of cytoplasmic transcription factors that mediate normal cellular responses to
cytokines, growth factors, and other polypeptide ligands [135,136]. The activation of STATs
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is an important event for the regulation of cytokine and growth factor-induced cellular and
biological processes, including proliferation, differentiation, survival, apoptosis and
inflammation. The STAT family of proteins is comprised of seven structurally and
functionally related proteins: STAT1, 2, 3, 4, 5a, 5b, and 6. All of the family members share
six distinct domains: the N-terminal domain, the coiled-coil domain, the DNA-binding
domain, the linker domain, the Src homology 2 (SH2) domain, and the transactivation
domain which contains a critical tyrosine residue (Tyr705 in STAT3) at the C-terminus that
is phosphorylated during activation. STAT activation by phosphorylation is mediated by
growth factor receptor tyrosine kinases and cytoplasmic kinases, such as cytokine receptorassociated JAKs and Src family kinases. Phosphorylation induces STAT-STAT homodimer
complex formation via the interaction of the phosphorylated tyrosine of one monomer and
the SH2 domain of another [135,136]. From the cytoplasm, STATs translocate to the nucleus
where they regulate gene transcription by binding to specific DNA response elements [135].
Nuclear accumulation of STATs as monomers or dimers remains to be fully defined and may
involve several mechanisms [137], including active shuttling between the cytoplasm and
nucleus [138].
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In contrast to the transient STAT activation in normal cells, approximately 70% of many
human solid and hematological tumors display overexpression of STAT3 or constitutive
activation of STAT3. These results strongly implicate a major role for aberrantly active
STAT3 in tumor formation. Accumulating data show that constant STAT3 activation is
required for aberrant cell proliferation in carcinogenesis. In gastric cancer, STAT3 activation
by IL-26 mediates up-regulated expression of Bcl-2, Bcl-xL and c-Myc, which in turn
facilitates cell proliferation [139]. Activated STAT3 is involved in cell proliferation of
endometrial, bladder, colon and renal cancers [140–143]. STAT3 promotes cell survival in
esophageal, colon, gastric and other types of cancer [139,144,145]. On the contrary,
inhibition of STAT3 results in decreased proliferation and increased apoptosis in cancer
cells. The microRNA miRNA130b, which targets STAT3, inhibits proliferation in pancreatic
cancer cell [146] and STAT3 inhibitors also decrease cell proliferation and promote
apoptosis in breast cancer, colorectal cancer, gastric cancer and lung cancer [147–152].
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STAT3 interacts with several factors involved in angiogenesis which includes degradation of
the vascular basement membrane, vascular epithelial cell proliferation, migration and new
vessel formation [153]. STAT3 inhibition causes decreased angiogenesis by down-regulation
of metalloproteinase 2 (MMP-2), which has a role in degradation of vascular basement
membrane. Conversely, STAT3 activation induces elevated MMP-2 expression [154]. STAT3
also induces VEGF expression, which plays a crucial role in invasion and metastasis of
human cancers such as ovarian carcinoma [155]. Thus, inhibition of angiogenesis by
blocking STAT3 signaling would be an attractive strategy in preventing or delaying tumor
formation.
Studies using STAT3-deficient mice showed that STAT3 activation is engaged in both the
initiation and promotion stages in skin carcinogenesis [156]. Loss of STAT3 in K5.Cre ×
STAT3flox/flox mice resulted in a significant reduction of epidermal hyperproliferation
compared to control mice following TPA treatment [31,156]. Mechanistic studies showed
that recovery of cell cycle regulatory proteins cyclin D1 and cyclin E was delayed and c-myc
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expression was constantly downregulated in the epidermis of K5.Cre × STAT3flox/flox mice
after treatment with TPA in comparison to control mice. Thus, deletion of STAT3 in the
basal layer of epidermis inhibited TPA-induced epidermal hyperproliferation during tumor
promotion. Using the temporally regulated epidermis-specific STAT3-deficient mouse
model, temporal disruption of STAT3 at the stage of carcinogenesis initiation resulted in an
increased number of apoptotic cells following treatment with carcinogen 7,12dimethylbenz[a]anthracene (DMBA, initiation chemical of skin carcinogenesis) [157].
Inducible deletion of STAT3 in epidermis prior to DMBA treatment delayed tumor onset and
reduced the number of papillomas. Similarly, inducible deletion of STAT3 prior to TPA
treatment during the tumor promotion stage delayed tumor onset and tumor growth [157].
The epidermis-specific STAT3-deficient mouse model facilitated further study of this
important molecule in UVB-mediated skin carcinogenesis. UVB radiation is the prime risk
factor for nonmelanoma skin cancer in humans [158]. Following exposure to UVB, the level
of phosphorylated STAT3 (p-STAT3) is initially decreased, followed by a significant
increase at later time points in the mouse epidermis. The levels of STAT3 target genes, such
as cyclin D1, Bcl-xL, and c-Myc, followed the changes in activated STAT3 in response to
UVB irradiation [159]. Epidermal-specific STAT3-deficient mice were very sensitive to
UVB radiation as revealed by a higher number of sunburned mice and a high number of
apoptotic cells following UVB irradiation [160]. On the other hand, the epidermis of
K5.STAT3C (constitutive active STAT3 form) mice was resistant to UVB-induced apoptosis
[161]. These results demonstrate that STAT3 plays an important role in the development of
UVB-induced skin tumors through its effects on both proliferation and survival of
keratinocytes [162].
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As mentioned, STAT3 regulates gene expression involved in proliferation, apoptosis, and
angiogenesis. Also, STAT3 activation is required for both the initiation and promotion stages
during skin carcinogenesis. Therefore, targeting STAT3 using a specific inhibitor may be an
attractive cancer treatment approach. A number of small molecule compounds directly
inhibit the activity and function of STAT3 which have been developed for use in cancer
treatment and prevention. The three domains of STAT3 – NH-2 terminal domain, DNAbinding domain and SH2 domain – were selective targets for the development of STAT3
inhibitors, which block STAT3 function(s) and signaling by preventing phosphorylation,
dimerization, nuclear translocation and DNA binding [163,164]. Table 5 summarizes the
small molecular inhibitors targeting STAT3.
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Inhibitors targeting the SH2 Domain of STAT3.—The SH2 domain of STAT3 plays a
pivotal role in STAT3 activation by mediating the interaction of STAT3 with phosphorylated
tyrosine residues on the cytoplasmic region of any activated receptors. Inhibition of this
target can block the formation of STAT3 dimer and consequently inhibit nuclear
translocation and STAT3-dependent gene regulation. A peptide composed of PY*LKTK (Y*
is the phosphorylated tyrosine) was derived from the STAT SH2 domain-binding peptide
sequence. It can directly form a complex with STAT3 monomer and inhibit STAT3 activity
by disrupting STAT3 dimerization [165]. STA-21 is a natural compound that specifically
binds to SH2 domain and inhibits STAT3 dimerization and nuclear translocation [166].
LLL-3 is STA-21 derivative that possesses comparable anti-proliferative activity to STA-21
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but exhibits increased cell permeability [167]. Stattic selectively inhibits dimerization and
prevents STAT3 translocation to the nucleus [168]. As a result, stattic induces apoptosis in
breast cancer apoptosis. S3I-201, a salicylic acid derivative, blocks the formation of STAT3
homodimers through SH2 domain binding and inhibits proliferation of breast and
hepatocellular cancer cells in mice [169]. BP-1–102, a S3I-201 analog, inhibits STAT3 via
the same mechanism and selectively suppresses malignant cell growth, transformation,
survival and migration [170]. Additionally, this compound displays oral bioavailability. S3IM2001, an oxazole-based peptidomimetic, selectively blocks STAT3 dimerization and
inhibits STAT3 dependent transcription, transformation, survival and migration [171].
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Inhibitors targeting the DNA binding domain of STAT3.—To regulate gene
expression, it is essential for the STAT3 DNA-binding domain (DBD) to physically interact
with the consensus DNA-binding sequence in the target gene’s promoter. Thus, STAT3
activity can be inhibited by targeting the STAT3 DBD to prevent interaction with the target
gene’s promoter and thus block its tumor-promoting functions. Hypermethylated in cancer 1
(HIC1) gene naturally forms a complex with STAT3 protein via direct binding between the
C-terminal domain of HIC1 and the STAT3 DBD [172]. This interaction prevents STAT3
binding to the promoters of its target genes, such as VEGF and c-myc. Platinum compounds,
such as CPA-1 and CPA-7 inhibit STAT3 DNA binding, hence suppressing cell growth and
increasing cell death in several human cancers. More recently, another platinum compound,
IS3–295, was shown to inhibit STAT3 DNA binding capability although its mechanism
remains unclear [173]. DBD-1, a small peptide aptamer, also blocks STAT3 DNA binding
and induces significant apoptosis in murine melanoma cells [174]. More recently, the
compound InS3–54 was identified; it inhibits STAT3 activity and it is capable of inducing
apoptosis in breast and lung cancer cell lines [175].
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Inhibitors targeting the STAT3 N-terminal domain.—The N-terminal domain of
STAT3 comprises ~130 amino acids and contains eight helices, which have multiple
biological activities, including dimer formation, binding to promoter and assembly of
transcriptional machinery [176,177]. Compounds targeting the N-terminal domain of STAT3
may therefore inhibit tumorigenesis. ST3-H2A2, a synthetic compound, binds to the STAT3
N-terminal domain and activates expression of proapoptotic genes, thereby initiating
apoptosis in cancer cells [178].
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Oligonucleotide approaches to inhibit STAT3 signaling.—Approaches targeting
gene expression based on oligonucleotide technology include antisense RNA, small
interfering RNA (siRNA), and decoy oligodeoxynucleotide (ODN). The knockdown of the
STAT3 protein by antisense RNA or siRNA approaches has been demonstrated in studies
which showed the induction of tumor cell apoptosis and tumor regression following loss of
STAT3 expression [179–181]. A STAT3-decoy oligonucleotide (ODN) can trap an activated
STAT3 dimer in the cytoplasm by inhibiting interaction between active STAT3 and importin,
which can result in increased apoptosis in colorectal cancer cells [182]. Also, ODN is a
competitive inhibitor of STAT3, and thereby can suppress STAT3-dependent transcription of
genes such as cyclin D, c-Myc, Survivin, and Bcl-xL [183]. Decreased expression of these
genes inhibits proliferation and increases apoptosis in tumor cell lines [184,185].
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The PI3K/AKT pathway is activated by various different cellular factors, including binding
of ligands to RTKs and G-protein coupled receptors and GTP binding of RAS proteins.
These signals activate the catalytic activity of PI3K, which consists of the regulatory (p85)
subunit, harboring two SH2 domains, and the catalytic (p110) subunit. PI3K phosphorylates
the 3’ position of the inositol ring of lipids in the cytosolic membrane, resulting in the
production of phosphatidylinositol-(3,4)-P2 (PIP2) and phosphatidylinositol-(3,4,5)-P3
(PIP3). PIP2 and PIP3 interact with pleckstrin homology (PH) domains of intracellular
proteins, resulting in the localization of PH domain containing proteins to the inner surface
of the plasma membrane. One such protein is AKT (also known as protein kinase B, or
PKB), which was initially identified as the oncogene in a transforming murine retrovirus
[186]. AKT, which has three homologous isoforms (AKT1, AKT2, AKT3), is a serinethreonine kinase that normally exists in the cytoplasm in an inactive state [187]. All three
isoform possess a similar structure: an N-terminal PH domain, a central S/T catalytic
domain and a C-terminal regulatory domain. After activation of PI3K, AKT is translocated
to the cell membrane where it is phosphorylated at two regulatory sites, Thr308 and Ser473.
The Thr308 residue, which is in the catalytic domain of AKT, is phosphorylated by
phosphoinositide-dependent kinase 1, which is another PH domain containing kinase that is
recruited to the plasma membrane [188,189]. Members of the PI3K-related kinase family,
including DNA-PK also phosphorylate AKT at Ser473. The Ser473 residue is in the
regulatory domain and is phosphorylated in response to growth factor stimulation by the
mechanistic target of rapamycin complex 2 (mTORC2) complex, which contains one of the
PI3K-AKT pathways’ important downstream effectors, mTOR [190]. The activity of the
PI3K-AKT pathway is regulated by the lipid phosphatase PTEN. PTEN dephosphorylates
the 3’ position of PIP2 and PIP3 and thus directly antagonizes the activity of PI3K. Loss of
PTEN results in constitutive activation of AKT.
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AKT phosphorylates proteins that contain the R-X-R-X-X-S/T-B motif. The first AKT
substrate identified was glycogen synthase kinase 3, which is an important metabolic
enzyme and also a key node of other signaling cascades [191]. AKT modulates cellular
proliferation, survival and cell cycle progression by phosphorylating numerous substrates,
such as BAD, CDK inhibitors p21 and p27, MDM2, IKK-alpha and caspase 9 [192]. AKT
regulates a variety of processes by inhibiting the function of the FOXO transcription factors,
which are localized to the cytoplasm following phosphorylation by AKT [193]. Also, AKT
regulates cellular metabolism, proliferation and survival through its effects on mTOR
signaling, which is activated by AKT’s inhibitory phosphorylation of TSC2 [194,195]. AKT
activity has also been shown to play a critical role in the regulation of other important
cellular behaviors, including motility, invasion, and angiogenesis [187].
As previously mentioned, activation of the PI3K/AKT signaling pathway contributes to cell
proliferation, survival and motility as well as angiogenesis, and thereby contributes to all the
important aspects of tumorigenesis and tumor metastasis. Evidence has shown that AKT is
overexpressed or activated in a variety of human cancers, including lung, breast, ovarian,
gastric and pancreatic carcinomas [196]. Therefore, PI3K/AKT is considered to be an
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attractive target for cancer therapy and many specific inhibitors with acceptable
pharmaceutical properties have been identified and developed (Table 6).
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Inhibitors targeting PI3K.—Two well-known PI3K inhibitors are the fungal metabolite
wortmannin and LY294002. Wortmannin binds irreversibly to PI3K enzymes through
covalent modification of a lysine essential for catalytic activity, whereas LY294002 is a
classical reversible, ATP-competitive PI3K modulator in micromolar concentration.
However, both wortmannin and LY294004 have little or no selectivity for individual PI3K
isoforms and show substantial toxicity in animals [197,198]. In spite of the crossover
inhibition of other lipid and protein kinases and their pharmaceutical properties, the
preclinical studies of these PI3K inhibitors have greatly contributed to understanding the
biological importance of PI3K signaling in the signal transduction network of human
cancers and provided a platform for the discovery of novel PI3K inhibitors. At present,
numerous PI3K-targeted compounds have been developed and introduced to clinical trials
(Table 6). BEZ235 (dactolisib) is an imidazoquinazoline derivative that inhibits multiple
class I PI3K isoforms and mTOR kinase activity via binding to the ATP-binding site of these
enzymes [199]. BEZ235 showed strong anti-proliferative activity against tumor xenografts
showing abnormal PI3K signaling including loss of PTEN function or PI3K gain of function
mutations [200]. BGT226 is another potent pan-PI3K/mTOR inhibitor similar to BEZ235
[201]. Unlike BEZ235 and BGT226, BKM120 (buparlisib) is selective for class I PI3K
enzymes with no mTOR inhibitory activity and it is capable of inducing apoptotic cell death
in multiple myeloma cells [202]. GDC0941 (pictilisib), a thienopyrimidine derivative,
inhibits all isoforms of class I PI3Ks in a nanomolar concentration [203]. It displayed potent
antitumor activity against a panel of mouse xenograft models of human glioblastoma, breast
cancer, small bowel gastrointestinal stromal tumor, follicular cell lymphoma and it is the
first PI3K inhibitor to enter clinical trials in patients with advanced solid tumors or
lymphoma. SF1126 is a covalent conjugate of LY294002 with an RGD (arg-gly-asp) peptide
designed for increased solubility and enhanced delivery of the active PI3K inhibitor to the
tumor resulting in significant antitumor activity in xenograft models [204]. In addition to its
direct activity on cancer cells, SF1126 also had significant antiangiogenic activity in vivo
with lowered toxicity compared to the LY294002. A number of compounds that
preferentially target selected isoforms of class I PI3Ks are also under development. For
example, PX-866 targets p110α, p110δ and p110γ with nanomolar half-maximal inhibitory
concentration (IC50) values, while CAL-101 (idelalisib) is a p110 γ-selective inhibitor
[205,206].
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Inhibitors targeting AKT.—As the most well-known downstream effector of the RTK/
PI3K complex, AKT is another attractive therapeutic target. Several AKT inhibitors have
been developed, which can be grouped into a number of classes including lipid-based
phosphatidylinositol analogs, ATP competitive inhibitors, and allosteric inhibitors. KRX
0401 (perifosine), the most clinically advanced inhibitor, is a lipid-based PI analog that
targets the PH domain of AKT, thereby preventing binding to PIP3 and its membrane
translocation [207]. In several preclinical models, such as the murine neuroblastoma model,
KRX 0401 demonstrated substantial activity. Other AKT PH domain inhibitors, including
PX316 and PIAs, showed inhibitory effects on the growth of tumor cells exhibiting
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increased PI3K/ AKT activity [208–210]. Most ATP-competitive AKT inhibitors are nonselective, targeting all AKT isoforms. GSK690693 is an ATP-competitive AKT kinase
inhibitor, which targets all three AKT isoforms at nanomolar concentrations and is also
active against additional kinases from the cAMP-dependent protein kinase C family [211].
In xenograft models, administration of GSK690693 led to significant growth inhibition in
mice bearing SKOV-3 ovarian cancer cells, BT474 breast cancer cells and LNCap prostate
cancer cells. AZD5363, another ATP-competitive inhibitor, inhibited all AKT isoforms
[212]. Treatment with AZD5363 inhibited proliferation of 41 out of 182 solid and
hematological tumor cell lines with the highest frequency of sensitivity occurring in breast
cancer cells. Several clinical trials in phase I and II are being undertaken for breast, prostate
and gastric cancers. GSK2110183 (afuresertib) is a highly potent inhibitor of AKT and
showed the most sensitivity within hematological cell lines, such as acute lymphoblastic
leukemia amd chronic lymphocytic leukemia [213]. GSK2141795 (uprosertib) is an analog
of GSK2110183, the difference being the substitution of a bioisostere furan ring for a
thiophene core [214]. This compound showed a similar capacity for AKT inhibition and
subsequently, had a similar anti-proliferative effect as GSK2110183 but it demonstrated
outstanding off-target kinase inhibition. ATP-competitive inhibitors are non-selective against
AKT isozymes and are inadequately selective against similar kinases. GDC-0068
(ipatasertib) is an orally bioavailable inhibitor capable of inhibiting all three AKT isoforms.
Treatment with GDC-0068 blocked cell cycle progression and decreased viability of cancer
cell lines [215]. To address a major issue regarding the potential benefits of isoform
specificity, efforts to identify AKT-specific and isoform-selective inhibitors have resulted in
the discovery of allosteric inhibitors. These allosteric AKT inhibitors have exhibited isoform
selectivity, reduced side-effects and lower toxicity [216]. AKTi-1/2, a naphthyridinone
allosteric dual inhibitor of AKT1 and AKT2, showed potent antitumor activity in tumor
xenograft models, and its analogue MK2206 led to around 60 % growth inhibition in ovarian
cancer cell line. In preclinical studies, MK-2206 showed significant synergistic effect when
combined with other chemotherapeutic drugs [217]. NSC-154020 (triciribine), a tricyclic
purine nucleoside derivative, strongly inhibited cell growth and induced apoptosis in human
cancer cell [218].

Author Manuscript
Author Manuscript

MAPK/ERK
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MAPKs/extracellular signal-regulated kinases (ERKs) are serine/threonine kinases that
mediate extracellular stimuli into a wide range of cellular responses including cell
proliferation, differentiation, survival, death and transformation [219,220]. MAPK pathways
incorporate a three-step kinase series in which MAPK is activated upon phosphorylation by
MAPK kinase (MAPKK, MEK), which in turn is activated when it phosphorylated by
MAPKK kinase (MAPKKK, MEKK, Raf). The ERK1 and ERK2 MAPKs are activated by
mitogens and were found to be upregulated in human tumors. Components of the ERK
signaling cascade are frequently mutated in cancer, with mutations occurring in
approximately one-third of human tumors [219]. The mechanism(s) whereby growth factors
and mitogens activate ERK signaling is of particular relevance to human cancer.
Consequently, inhibitors targeting components of the ERK signaling pathway have been
developed to be used as cancer therapeutics [220]. Two other major MAPK pathways, the
Jun N-terminal kinase (JNK) and p38 MAPK pathways, which are referred to as the stress
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activated protein kinase pathways, are also often deregulated in cancers. JNKs and p38
MAPKs are activated by environmental and genotoxic stresses and have key roles in
inflammation, as well as in tissue homeostasis given that they control cell proliferation,
differentiation, survival and the migration of specific cell types [221–225]. The expression
or activity of JNK and p38 MAPK pathway components is often altered in human tumors
and cancer cell lines. Given the many tumorigenesis-related functions that these kinases can
control, both in the cancer cell and in the tumor microenvironment, it is important to
carefully consider the type of tumor before attempting to modulate these pathways for
cancer therapy. Here, we focused on the basic and progressing research on MEK-ERK
MAPK signaling inhibitors and its implications.
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Inhibitors targeting ERK signaling.—In the ERK/MAPK module, ERK is activated
upon phosphorylation by MEK, thus MEK also has been a target for anticancer drug
development for almost 15 years [226] (Table 7). Trametinib (GSK1120212; GSK) became
the first MEK inhibitor to be approved by the US Food and Drug Administration (FDA) for
the treatment of metastatic melanoma with the BRAF(V600E/K) mutation [227]. It is a
potent inhibitor of both MEK1/2 that, unlike the MEK inhibitors discussed above,
preferentially binds to dephosphorylated MEK1/2 and prevents RAF-dependent MEK
phosphorylation and activation. PD0325901, with a IC50 of 1 nM against purified MEK1
and MEK2, showed significant antitumor activity in several in vitro and in vivo models
[228]. The anticancer drug activity also has been demonstrated in a variety of human tumor
xenografts. AZD6244 (selumetinib) is an oral potent second generation inhibitor [229]. This
is another allosteric MEK1 and MEK2 inhibitor that is highly selective for MEK1/2 with an
IC50 of 14nM against purified MEK1/2. GDC-0973 (cobimetinib) is an oral active inhibitor
of MEK1/2 [230]. In vitro studies demonstrated it was able to inhibit ERK1/2
phosphorylation at nanomolar range and it demonstrated antiproliferative effects on multiple
tumor cell lines. RO5126766 is a potent and selective dual RAF/MEK inhibitor and it was
more effective at reducing colony formation than other MEK inhibitors [231]. In addition,
this compound suppressed tumor growth in a SK-MEL-2 xenograft model.
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Activated ERK regulates a number of cellular events, including cell proliferation and
survival [232,233]. In contrast to the advanced development and evaluation of RAF and
MEK inhibitors, there has been limited progress in the development of ERK1- and ERK2selective inhibitors. This is partly due to the earlier assumption that, as ERK is the only
known downstream target of MEK, no additive benefit would result from an ERK inhibitor
compared to a MEK inhibitor. Thus, development of ERK inhibitors lagged behind
RAF/MEK inhibitors. However, interest in the discovery and development of ERK inhibitors
has recently intensified, for several reasons. First, after the experience with RAF and MEK
inhibitors, there has been an increasing appreciation of the complexity and diversity of the
biochemical effects of different small-molecule inhibitors targeting components of the same
pathway. Second, the negative feedback loops that are promoted by small-molecule
inhibitors of different components of the ERK signaling cascade may show important
differences depending on the molecule that is targeted. Finally, resistance to RAF and MEK
inhibitors frequently involves the recovery of ERK signaling, suggesting the potential use of
an ERK inhibitor [234]. To date, a few potent and selective cell-active preclinical ERK
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inhibitors have been described in the patent literature. SCH772984 is an ATP-competitive
ERK1 and ERK2 inhibitor that was derived from an affinity-based high throughput screen
for small molecules that bind to the dephosphorylated, or inactive, form of ERK2 [235].
Binding of SCH772984 to ERK results in a dual mechanism of inhibition: inhibition of
ERK1 and ERK2 intrinsic kinase activity and the prevention of phosphorylation of ERK1
and ERK2 by MEK. This latter activity is thought to occur as a result of a large
conformational change induced by SCH772984 binding, which opens up a new side pocket
on ERK [235,236]. SCH772984 inhibited cellular proliferation and induced apoptosis
selectively in tumor cell lines that carry RAS or BRAF mutations, and it induced significant
tumor regression in mice with BRAF- or RAS-mutant xenografts. SCH772984 also
demonstrated activity in cells that were resistant to either BRAF or MEK inhibitors and in
cells that became resistant to the dual combination of these inhibitors. SCH900353, a
clinical grade analogue of SCH772984, is currently being tested in Phase I clinical trials.
VTX-11e is a potent, selective, and orally bioavailable ERK2 inhibitor with Ki of < 2 nM
[237].

PTPS IN CARCINOGENESIS AND ITS POTENTIAL APPLICATION
PTPs with potential tumor suppressive function
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As previously mentioned, PTPs can antagonize oncogenic PTK signaling by catalyzing the
reverse function of PTKs. In this regard, the function of PTPs as tumor suppressors have
been studied in various cancers. A mutational analysis of the PTP gene superfamily in
human colorectal cancer through systematic sequencing revealed 83 somatic mutations in
six PTP genes, including three members of the receptor-like PTP subfamily (PTPRF,
PTPRG, and PTPRT) and three members of the nonreceptor-like PTP subfamily (PTPN3,
PTPN13, and PTPN14) [238]. Fifteen mutations of the 83 somatic mutations detected were
nonsense, frameshift, or splice-site alterations that were predicted to result in truncated
proteins lacking phosphatase activity. In this study, the most frequently mutated PTP gene
was PTPRT. Biochemical analysis of five missense mutations of PTPRT indicated that these
mutations reduced phosphatase activity of PTPRT. Consistent with this observation,
exogenous expression of wild-type PTPRT in HCT116 and DLD1 colorectal cancer cells
significantly inhibited cell growth, whereas mutant PTPRT expression did not have an effect
on cancer cell growth [238], suggesting that PTPRT functions as a tumor suppressor in
colorectal cancer. High-frequency microsatellite instability (MSI-H), which is characterized
by length alterations within simple repeated sequences, is induced by defective DNA
mismatch repair [239]. An analysis of 54 MSI-H colorectal cancers identified frameshift
mutations in six PTP genes, including three members of the receptor-like PTP subfamily
(PTPRA, PTPRS, and PTPRE) and three members of the nonreceptor-like PTP subfamily
(PTPN21, PTPN5, and PTPN23) [240]. These studies showed that about 32% of MSI-H
tumors had frameshift mutations in at least one of the six PTP genes identified, with the
highest mutation frequency occurring in PTPN21. Recent studies using whole-exome
sequencing to identify novel risk factors for early-onset of colorectal cancers revealed that
PTPN12 is a potential candidate that can contribute to the heterogeneous susceptibility to
colorectal cancer [241].
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Genetic alterations of PTPs were also found in other human cancers [15,242]. For example,
loss of function mutations in receptor-like PTPs, such as PTPRT, PTPRC, PTPRD, and
PTPRM, were found in head and neck squamous cell carcinoma (HNSCC) [243]. In
particular, PTPRT has been found to be the most frequently mutated PTP gene in human
cancers [244,245]. According to the Catalogue Of Somatic Mutations In Cancer (COSMIC)
(http://cancer/sanger.ac.uk/cancergenome/projects/cosmic/), PTPRT mutations have been
identified in a variety of human cancers including colon (11%), bladder (6%), endometrium
(8%), esophagus (11%), head and neck (6%), lung (10%), and stomach (9%) cancers
[238,243,244]. One oncogenic substrate of PTPRT that has been identified is STAT3 and
overexpression of PTPRT in colorectal cancer cells reduced the expression of STAT3 target
genes [246]. In accordance with this observation, HNSCC tumors harboring PTPRT
mutations exhibited a significantly higher level of phosphorylated, or activated, STAT3
compared with HNSCC tumors without mutation. Overexpression of wild-type PTPRT in
HNSCC cells reduced the level of phosphorylated STAT3 expression, whereas expression of
mutant PTPRT increased the level of phosphorylated STAT3 expression [243]. In addition to
somatic mutations of PTPRT gene, the analysis of the Cancer Genome Atlas (TCGA)
showed that the PTPRT promoter is frequently hypermethylated in HNSCC tumors which
was associated with the downregulation of PTPRT mRNA expression and upregulation of
phosphorylated STAT3 expression. Further, mouse xenograft study using HNSCC cells with
PTPRT methylation demonstrated that increased PTPRT promoter methylation is associated
with increased sensitivity to STAT3 inhibition [247].
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Functional studies including work with PTP-specific transgenic mouse models have
provided in vivo evidence that PTPs can function tumor suppressors. Generation of PTPRT
knockout mice showed that PTPRT deficiency increased levels of colonic paxillin
phosphorylation at residue Y88 and increased the susceptibility to carcinogen
azoxymethane-induced colon tumor development [248]. PTPRD, also known as PTPR-delta,
is a receptor-like PTP that has been shown to be involved in the regulation of cell growth,
migration, and angiogenesis [15,242]. PTPRD inactivation was found in different cancers
including glioblastoma multiforme (GBM) [249–251]. Studies showed that STAT3 is one of
the substrates of PTPRD and mutations of PTPRD abrogate the ability of this phosphatase to
dephosphorylate STAT3 [252]. Increased levels of phosphorylated STAT3 have frequently
been found in solid tumors including GBM [253,254]. Recent studies using PTPRDknockout mice showed that PTPRD deficiency promotes gliomagenesis corresponding with
the accumulation of phosphorylated STAT3 and STAT3 hyperactivation [255].
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T-cell protein tyrosine phosphatase (TC-PTP; encoded by PTPN2) is one of 17 intracellular
and non-receptor PTPs and was originally cloned from a human T-cell cDNA library
[256,257]. It has been shown that TC-PTP is involved in the regulation of various
physiological functions including cell cycle regulation and apoptosis through
dephosphorylation of its target substrates, such as JAK1, JAK3, STAT1, STAT3 and STAT5
[258,259]. Recent studies revealed that focal deletion of PTPN2 was detected in human Tcell acute lymphoblastic leukemia, suggesting TC-PTP has the potential to act as a tumor
suppressor [260]. In accordance with this observation, studies have shown that TC-PTP has
a tumor suppressive function in breast and colorectal cancers mainly through its regulation
of STAT3 signaling [261,262]. Decreased levels of TC-PTP expression was detected in a
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subset of breast cancer cell lines and a large proportion of triple-negative primary human
breast cancers. In addition, TC-PTP overexpression in human breast cancer cell lines
suppressed cell proliferation and anchorage-independent growth with reduced tyrosine
phosphorylation of STAT3 and SRC family kinase [261]. GdX (X-linked gene in the G6PD
cluster at Xq28) is known to act as a chaperon in protein processing in the endoplasmic
reticulum [263,264]. Studies showed that GdX stabilizes the steady-state association of
phosphorylated STAT3 with TC45, a nuclear form of TC-PTP, and promotes STAT3
dephosphorylation. Deletion of GdX in mice significantly accelerated colitis-associated
colorectal tumorigenesis that corresponded with an increased level of phosphorylated STAT3
[262].
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The Src homology 2 domain-containing PTP-1 (SHP-1; encoded by PTPN6) is a nonreceptor PTP that is expressed most abundantly in hematopoietic cells [265]. Loss of SHP-1
expression was frequently found in anaplastic lymphoma kinase (ALK)-positive anaplastic
large cell lymphoma (ALK+ ALCL), a type of non-Hodgkin lymphoma of T/null-cell
immunophenotype [266]. Transfection and expression of exogenous SHP-1 in SHP-1negative ALK+ ALCL cell lines significantly reduced phosphorylated JAK3 and
phosphorylated STAT3 and, consequently, the downregulation of STAT3 downstream
targets. In contrast, knockdown of SHP-1 with siRNA in SHP-1-positive ALK+ ALCL cell
lines increased the levels of phosphorylated JAK3 and phosphorylated STAT3 [267]. SHP-1
was also involved in the induction of apoptosis in epithelial cancer cells by downregulating
phosphorylated STAT3. Increased SHP-1 activity induced by sorafenib or its derivatives
inhibited STAT3 phosphorylation, which contributed to the increase in apoptosis in breast
cancer and hepatocellular carcinoma cell lines [268,269]. Regorafenib, an inhibitor of
multiple protein kinases that has anti-tumor and anti-metastatic capabilities in metastatic
colorectal cancer, triggered apoptotic cell death by decreasing STAT3 phosphorylation
through enhanced SHP-1 activity [270].
SHP-2, which is encoded by PTPN11, is a ubiquitously expressed PTP that plays an
important role in developmental process and its germline mutations are known to cause both
Noonan syndrome and LEOPARD syndrome, two clinically similar autosomal dominant
developmental disorders [271]. Generation of hepatocyte-specific SHP-2 knockout mice
showed that SHP-2 deficiency significantly promoted diethylnitrosamine-induced
hepatocellular carcinoma development with increased STAT3 signaling [272].
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Studies indicate that constitutive activation of STAT3, a common substrate of PTPs, is found
in human tumors and cancer cell lines, and its inhibition can suppress the growth of cancer
cells, implying that it possesses a critical role in cancer cell proliferation. In this regard,
STAT3 signaling was downregulated by PTPs in different models of carcinogenesis (Table
8). These results suggest that elucidation of the cellular signaling mechanism(s) that regulate
STAT3 phosphorylation/dephosphorylating will be important for cancer prevention and the
development of more effective cancer treatments.
While the frequent mutation/inactivation of PTPs in human cancers which result in tumor
suppressive roles for PTPs that has been observed in in vitro cell culture systems was
confirmed by in vivo transgenic mouse models in most cases, other recent studies showed
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that there is a discrepancy between the potential tumor suppressive role of PTPs and their
actual effects on in vivo tumorigenesis. As already mentioned, HNSCC tumors can express
somatic mutations of the PTPRT gene or hypermethylation of the PTPRT promoter and
theses alterations resulted in an increased expression of phosphorylated STAT3 [243,247].
However, PTPRT-knockout mice were not more susceptible to 4-nitroquinoline 1-oxide (4NQO)-induced HNSCC carcinogenesis compared to wild-type mice [273]. Stattic is a
nonpeptidic small molecule that selectively inhibits the function of the STAT3 SH2 domain
and prevents its activation, dimerization, and nuclear translocation [168]. Even though
targeting of STAT3 with stattic resulted in a chemopreventive effect against 4-NQO-induced
oral carcinogenesis, both PTPRT-knockout and wild type mice responded similarly to statticmediated chemoprevention [273]. These results indicate that functional loss of PTPRT in
mice does not support its tumor suppressive role with the phenotype of mutation or promoter
methylation in this model of carcinogenesis. There are several possible explanations for this
discrepancy. First, it is possible that the C57BL/6J mice used in this study were sensitive to
4-NQO, whereas this genotype of mice were resistant to azoxymethane because PTPRTknockout mice showed increased susceptibility to azoxymethane-induced colon
carcinogenesis [248]. Second, it is possible that PTPRT may have divergent or pleiotropic
roles in oral and colonic epithelium during carcinogenesis [273]. Third, it may be that the
redundant regulation of STAT3 signaling by other PTPs can compensate for the loss of
PTPRT in oral carcinogenesis induced by 4-NQO. Finally, 4-NQO treatment or cell
signaling pathways activated by 4-NQO treatment may cause the inhibition of PTPRT
activity.
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Collectively, genetic mutation analysis in human cancers and subsequent functional studies
using transgenic mice have suggested that PTPs play a critical role in attenuating
carcinogenesis by inhibiting oncogenic signaling pathways, such as STAT3 signaling. It
further suggests that development of small molecule PTP activators will be another efficient
strategy for targeted cancer therapy, in addition to PTK inhibitors.
Tumor suppressive PTPs in skin carcinogenesis
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As previously mentioned, PTKs have been shown to play a prominent role in skin
carcinogenesis. Consequently, PTPs also can function in skin cancer though their exact role
is less well-characterized. For example, PTP expression is known to be induced during the
proliferation and maturation of keratinocytes but paradoxically their expression levels
remain unchanged within epidermal tissue [274]. Still, microarray analysis of human
melanoma tissues revealed that expression of PTPs, such as PTPκ and PTPλ, decreases in
human melanoma when compared with analogous noncancerous tissue [275,276], indicating
a tumor suppressor role for PTPs. Also, exposure to acute UV radiation increases the ligandindependent activation of PTKs [277,278]. One possible explanation for this result would be
that UV irradiation induces PTP inactivation in order to allow for the activation PTKs. In
fact, biochemical studies revealed that reactive oxygen species (such as H2O2) produced by
UV irradiation caused the inactivation of PTPs by oxidizing the cysteine residue within the
conserved active-site of the PTP catalytic domain [279–281]. Furthermore, studies from
different groups have demonstrated that acute UV irradiation resulted in the inactivation of
PTPs, such as PTPκ, in keratinocytes as well [282,283].
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Recent studies have shown that STAT3 plays an important role in UVB-mediated skin
carcinogenesis. In this regard, STAT3-overexpressing keratinocytes were resistant to UVBinduced epidermal apoptosis, whereas STAT3-deficient keratinocytes were sensitive to
UVB-induced apoptosis compared with control keratinocytes [160]. Further studies using
transgenic mice either deficient in STAT3 or expressing constitutively active STAT3 in
keratinocytes demonstrated a critical role for STAT3 in UVB-mediated skin carcinogenesis
[161]. While STAT3 has a role in skin cancer formation, UVB irradiation initially caused
rapid STAT3 dephosphorylation in keratinocytes and pretreatment of sodium vanadate, a pan
PTP inhibitor, desensitized keratinocytes to UVB-induced apoptosis corresponding with the
recovery of phosphorylated STAT3 expression, suggesting the involvement of PTPs in this
mechanism [160]. Further studies showed that three PTPs, TC-PTP, SHP-1, and SHP-2, can
cooperate in the dephosphorylation of STAT3 in response to UVB irradiation. Following
irradiation of mouse skin with UVB, the protein expression level of phosphorylated STAT3
in the epidermis was reduced, though the level recovered at later time points [159]. It
suggests that PTP-mediated signaling may serve as part of a protective mechanism against
skin carcinogenesis. Knockdown of each of these three PTPs using siRNA revealed that only
TC-PTP had a major effect on STAT3 regulation in skin keratinocytes. The level of
phosphorylated STAT3 in TC-PTP knockdown keratinocytes was higher relative to SHP-1
knockdown or SHP-2 knockdown keratinocytes, implying that TC-PTP has a greater effect
on STAT3 dephosphorylation than the other two PTPs [284]. In this regard, TC-PTP
deficiency in keratinocytes significantly reduced UVB-induced apoptosis with increased cell
proliferation. TC-PTP activity was increased in response to UVB irradiation, and
overexpression of TC-PTP in keratinocytes showed greater increased activity in the presence
of UVB [284]. These studies suggest that TC-PTP may be a novel therapeutic target for the
prevention of UVB-induced skin cancer. Identification of the mechanism of UVB-induced
PTP activation using a TC-PTP specific transgenic mouse model will be helpful to
understand the PTP-mediated protective mechanism in skin carcinogenesis and so that it can
be applied to the prevention of skin cancer.
PTPs with potential oncogenic function
While PTPs initially were thought to be potential tumor suppressors as they appear to be in
skin cancer, studies have shown that PTPs can also promote tumorigenesis by triggering
negative-feedback mechanisms that terminate activation signals or by dephosphorylating the
inhibitory factors of oncogenic PTK signaling pathways. In this section, we discuss two
oncogenic PTPs, SHP-2 and PTP1B and the recent development of their inhibitors.
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Despite its tumor suppressive role in hepatocellular carcinogenesis [272], SHP-2 primarily
has been identified as an oncogenic PTP for the following reasons: a) it can mediate the
activation of the Ras-ERK pathways by growth factors, cytokines, and hormones; b) several
types of leukemia possess mutations that activate SHP-2 [285–287]. In this regard, inhibitors
targeting SHP-2 have been identified and/or developed. Chen et al. identified Fumosorinone
as a potent SHP-2 inhibitor [288]. Fumosorinone, which originates from entomogenous
fungi, exhibited selective inhibition of SHP-2 over other PTPs tested. Fumosorinone
effectively inhibited SHP-2-dependent activation of the Ras-ERK signaling pathway
downstream of EGFR, while it had little effect on SHP-2-independent ERK activation
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induced by TPA [288]. Recently, the highly potent, selective and orally bioavailable small
molecule inhibitor SHP099 was also developed [289]. SHP099 inhibited SHP-2 activity
through an allosteric mechanism by binding to the interface of the N-terminal SH2, Cterminal SH2, and PTP activation domain. SHP099 inhibited the proliferation of RTK-driven
human cancer cells by suppressing Ras-ERK signaling pathway [289].
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PTP1B, which is encoded by PTPN1, is an intracellular and non-receptor PTP that has a
critical role in diabetes and obesity and which also has been shown to function as a tumor
promoter [290]. PTP1B overexpression was found in human breast cancers. Its
overexpression was observed in more than 70% of mammary tumor sections compared with
normal counterparts [291]. PTP1B increased c-Src activity by dephosphorylating it negative
regulatory site, tyrosine-530 in human breast cancer cell lines [292]. PTP1B has been
implicated in gastric carcinogenesis as a potential oncogenic PTP as well. PTP1B increased
gastric cancer cell proliferation and survival by regulating Src-mediated signaling pathways.
Further clinicopathological examination of gastric cancer patients indicated that PTP1B
amplification is associated with poor survival of gastric cancer patients [293]. In this regard,
the small molecule inhibitor MSI-1436, which can inhibit PTP1B by targeting its disordered
C terminal noncatalytic domain, has been identified as a potential anti-cancer drug.
MSI-1436 inhibited tumorigenesis in xenografts and abrogated metastasis in the NDL2
mouse model of breast cancer [294]. However, like SHP-2, PTP1B has demonstrated some
tumor suppressive capabilities. PTP1B was underexpressed in ovarian carcinoma-derived
cell lines and its expression decreased proliferation, migration, and invasion of ovarian
cancer cell lines through the dephosphorylation of the IGF-1R β-subunit and BRK/PTK6, a
Src-like PTK that physically and functionally interacts with the IGF-1R β-subunit [295].
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Taken together, studies have shown that PTPs also have a potential in promoting
carcinogenesis by activating oncogenic signaling pathways, such as Src signaling. It
suggests that development of small molecule PTP inhibitors to block PTP oncogenic
function could be a potential approach to prevent carcinogenesis dependent on the type of
cancer that is being targeting.

CONCLUDING REMARKS
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Tyrosine phosphorylation signaling is one major therapeutic target in carcinogenesis. PTKs
and their downstream signal transduction pathways are aberrantly activated in various
cancers. Specific inhibitors targeting PTKs and their downstream pathways have been
developed and used to kill cancer cells. However, most PTK inhibitors have not been able to
completely block cancer cell growth, even though they showed significant effects in
abrogating carcinogenesis in both in vitro cell lines and in vivo mouse models. This
reduction in efficacy may be due to more complex cancer signaling in humans, cancer
heterogeneity, and/or the development of drug resistance following long term treatment.
PTPs are involved in carcinogenesis as both tumor suppressors and tumor promoters. Like
PTK inhibitors, PTP inhibitors targeting oncogenic function have recently been developed.
However, the development of activators to target the tumor suppressive function(s) of PTPs
and the consequences of their application have not been investigated given the difficulty of
designing and creating specific activators of PTPs. In order to develop better therapeutic
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methods for preventing and treating cancer, we must better understand the function of
tyrosine phosphorylation signaling during carcinogenesis, create novel, more effective and
specific inhibitors of PTKs or PTPs, create tumor suppressive PTP activators, and investigate
the efficacy of the combinatorial use of these inhibitors and activators.
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4-NQO

4-nitroquinoline 1-oxide

ALK

anaplastic lymphoma kinase

ALCL

anaplastic large cell lymphoma

DBD

DNA-binding domain

DMBA

7,12-dimethylbenz[a]anthracene

EGF

epidermal growth factor

EGFR

epidermal growth factor receptor

ERK

extracellular signal-regulated kinases

GBM

glioblastoma multiforme

GdX

X-linked gene in the G6PD cluster at Xq28

HGH

human growth hormone

HIC1

hypermethylated in cancer 1

HNSCC

head and neck squamous cell carcinoma

IGF-1

insulin-like growth factor 1

IGFBP

insulin-like growth factor binding protein

IGF-1R

insulin-like growth factor 1 receptor

JAK

Janus kinase

JNK

Jun N-terminal kinase

MAPK

mitogen-activated protein kinase

MMP-2

metalloproteinase 2

MSI-H

high-frequency microsatellite instability

NSCLC

non-small-cell lung carcinoma
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mTOR

mechanistic target of rapamycin

ODN

oligodeoxynucleotide

PH

pleckstrin homology

PKC

protein kinase C

PTK

protein tyrosine kinase

PTP

protein tyrosine phosphatase

RTK

receptor tyrosine kinase

SFK

Src family of kinase

SH2

Src homology 2

SHP-1

Src homology 2 domain-containing PTP-1

siRNA

small interfering RNA

STAT3

signal transducer and activator of transcription 3

TC-PTP

T-cell protein tyrosine phosphatase

TGFα

transforming growth factor α

TPA

12-O-tetradecanoylphorbol-13-acetate

Tyr

tyrosine

UVB

ultraviolet B
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Figure 1. Schematic representation of the RTK signaling network and nodes of therapeutic
blockade.
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Activation of RTKs can result in signaling via two pathways: PI3/AKT and
RAS/RAF/MEK/ERK. PI3K/AKT signaling induces cell survival, increases protein
synthesis, activates glucose metabolism, and decreases apoptosis. RAS/RAF/MEK/ERK
increases cellular proliferation, angiogenesis, migration, and differentiation by activating
transcriptional factors in a cascade. Each ligand binds to RTK and transfers the extracellular
signal to the cytosol and then, ultimately, to the nucleus. Targeted therapy using monoclonal
antibody (-MAB or -IB) or TKI can block the extracellular signals which enter the cell
through the RTK pathway.
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Figure 2. The era of chemotherapy.

Since the discovery of nitrogen mustards and folic acid antagonist drugs in the 1940s, the
history of chemotherapy has begun. In the mid-2000s, when PTKs were discovered and
revealed to be involved in carcinogenesis, the approach toward chemotherapy evolved to
target specific cancer-associated molecules like PTKs. However, due to chemoresistance,
targeted therapy has still been challenged by combination chemotherapy in clinical trials.
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Figure 3. EGF/EGFR signal transduction and its targeted therapy.
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The binding of EGF to its receptor initiates a variety of signaling cascade via five main
pathways; 1) RAS/RAF/MAPK, 2) PI3K/AKT, 3) JAK/STAT, 4) PLCγ/PKC/Ca2+dependent, and 5) Src/FAK/MMP. Furthermore, the EGF/EGFR dimer can directly regulate
the expression of specific genes through an endocytosis mechanism. Constitutive activation
of EGFR as a result of mutation of the EGFR gene can promote cancer by facilitating DNA
synthesis, cell proliferation, angiogenesis, invasion, and metastasis. Ongoing clinical trials of
anticancer drugs, like monoclonal antibodies of the EFG binding site or small molecules
against the EGF catalytic domain, may prove to inhibit EGF/EGFR signaling by blocking its
autophosphorylation.
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Figure 4. The role of Src in cells.

Src may interact with a number of kinases which can regulate cell proliferation, migration,
adhesion, and angiogenesis. RTKs can trigger the phosphorylation of the Src Tyr416 residue
and promote activation of the transcription factor STAT3, which can regulate gene
expression to stimulate cell migration, angiogenesis, and cell survival. PI3K activation
following loss of PTEN may induce Src/AKT cascade signaling to enhance cell growth.
Moreover, Src can mediate cell adhesion and migration by interacting with catenin or
integrin/focal adhesion proteins, such as FAK, CSK, Paxillion, and RhoA.
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Targeted therapy for EGFR, ALK, and RET
Inhibitor

Target

Types of cancer

Gilotrif(Afatinib) [32]
Iressa (Gefitinib) [33]
Tarceva (Erlotinib) [34, 35]

NSCLC, pancreatic cancer, colon cancer, head and neck cancer
EGFR

Erbitux (Cetuximab) [36, 37]
Vectibix (Panitumumab) [38]
Portrazza (Necitumumab) [39]
Tagrisso (Osimertinib) [40]
Xalkori (Crizotinib) [43]
AP26113 (Brigatinib) [44]

Squamous cell lung cancer
EGFR (T790M)

Cancers failed with Gilotrif, Iressa or Tarceva

ALK

Lung cancer, metastatic NSCLC with ROS1 mutation

ALK, EGFR (T790M)

NSCLC

Author Manuscript

Alecensa (Alectinib) [41, 42]

ALK

Metastatic tumor in the brain, central nervous system

Zykadia (Ceritinib) [45, 46]

ALK

Metastatic tumor in the brain, central nervous system, NSCLC

RET

Thyroid cancer, prostate cancer, melanoma

Cometriq (Cabozantinib) [47, 48]
Caprelsa (Vandetanib) [49]
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Author Manuscript

Targeted therapy for IGF-1R
Inhibitor

Target

Types of cancer

IMC-A12 (Cixutumumab) [50, 51]

IGF-1R

Advanced nonsquamous NSCLC, metastatic docetaxel-pretreated castrationresistant prostate cancer

CP-751, 871 (Figitumumab) [52]

IGF-1R

Advanced solid tumor

MK-0646 (Dalotuzumab) [53, 54]

IGF-1R

Advanced solid tumor, KRAS wild-type, metastatic colorectal cancer

AMG 479 (Ganitumab) [55, 56]

IGF-1R

Mutant KRAS metastatic colorectal cancer, metastatic adenocarcinoma of the
pancreas

R1507 [57]

IGF-1R

Recurrent or refractory rhabdomyosarcoma, osteosarcoma, dynovial sarcoma,
other soft tissue sarcoma

SCH-717454 (Robatumumab) [58]

IGF-1R

Relapsed osteosarcoma and Ewing sarcoma

AVE1642 [59, 60]

IGF-1R

Advanced solid tumor

MEDI-573 [61, 62]

IGF-1R and IGF-2

Advanced solid tumor
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Small molecular inhibitors targeting IGF-1R
Inhibitor

Target

Types of cancer

OSI-906 (Linsitinib) [63]

TK/ATP-competitive

NSCLC

BMS-754807 [64, 65]

TK/ATP-competitive

Colorectal cancer, rhabdomyosarcoma, neuroblastoma, osteosarcoma, Ewing sarcoma,
and Wilms tumor

BVP-51004 [66]

Not ATP-competitive

Multiple myeloma
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Author Manuscript

Targeted therapy for Src
Inhibitor

Target

Types of cancer

BMS-354825 (Dasatinib) [67–72]

Src
Bcr-Abl
PDGFR
c-Kit
EphA2

HR/HER2-positive breast cancer, triple-negative breast cancer, castration-resistant prostate
cancer, NSCLC, colon cancer, HNSCC metastatic breast cancer, myeloid leukemia

AZD0530 (Saracatinib) [73]

Src
Bcr-Abl

castration-resistant prostate cancer

SKI-606 (Bosutinib) [74–78]

Src
Bcr-Abl

Myeloid leukemia, metastatic breast cancer
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Author Manuscript

Small molecular inhibitors targeting STAT3
Inhibitor

Author Manuscript

Target

Types of cancer/transformed cell lines

PY*LKTK [165]

SH2 domain

Transformed fibroblasts

STA-21 [166]

SH2 domain

Breast cancer

LLL-3 [167]

SH2 domain

Breast cancer

Stattic [168]

SH2 domain

Breast cancer

S3I-201 [169]

SH2 domain

Breast cancer, hepatocellular carcinoma

S3I-M2001 [170]

SH2 domain

Breast cancer, pancreatic cancer

BP-1–102 [171]

SH2 domain

Breast cancer, lung cancer

HIC 1 [172]

DNA binding domain

Breast cancer

IS3–295 [173]

DNA binding domain

Colon cancer

DBD-1 [174]

DNA binding domain

Melanoma

InS3–54 [175]

DNA binding domain

Breast cancer, lung cancer

N-terminal domain

Prostate cancer

SH2 domain

Head and neck cancer, breast cancer, prostate cancer

ST3-H2A2 [178]
G-quartet ODN [184, 185]
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Author Manuscript

Inhibitors targeting PI3K/AKT in clinical trials for cancer treatment
Inhibitor

Target

Types of cancer

BEZ235 (Dactolisib) [199, 200]

ATP competitive PI3K α/β/γ/δ

Glioblastoma multiforme, advanced breast cancer

ATP competitive PI3K α/β/γ

Solid tumors, advanced breast cancer

BKM-120 (Buparlisib) [202]

ATP competitive PI3K α/β/γ/δ

Breast cancer, glioblastoma multiforme

GDC-0941 (Pictilisib) [203]

ATP competitive PI3K α/δ

Advanced breast cancer, NSCLC, melanoma, pancreatic cancer

SF1126 [204]

ATP competitive PI3K α/β/δ

Advanced solid tumors

PX-866 [205]

ATP competitive PI3K α/γ/δ

Ovarian cancer, prostate cancer, glioblastoma multiforme

ATP competitive PI3K δ

Chronic lymphocytic leukemia, acute myeloid leukemia, nonHodgkin’s lymphoma

GSK690693 [211]

ATP competitive Akt 1/2/3

Acute lymphoblastic leukemia

AZD5363 [212]

ATP competitive Akt 1/2/3

Breast cancer, gastric cancer, prostate cancer

GSK2110183 (Afuresertib) [213]

ATP competitive Akt 1/2/3

Multiple myeloma

GSK2141795 (Uprosertib) [214]

ATP competitive Akt 1/2/3

Multiple myeloma

GDC-0068 (Ipatasertib) [215]

ATP competitive Akt 1/2/3

Triple-negative breast cancer

MK2206 [217]

Allosteric Akt 1/2/3

Advanced solid tumor

NSC-154020 (Triciribine) [218]

Allosteric Akt 1/2/3

Hematologic malignancies, NSCLC

BGT226 [201]

CAL-101 (Idelalisib) [206]
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Table 7.

Author Manuscript

Inhibitors targeting MEK/ERK signaling
Inhibitor

Target

Types of cancer

Trametinib (GSK) [227]

Allosteric MEK

Melanoma, colorectal cancer, neuroblastoma, lung cancer

PD0325901[228]

Allosteric MEK

Colorectal cancer, solid tumor,

Selumetinib [229]

Allosteric MEK

Triple-negative breast cancer, melanoma, lung cancer, head and neck carcinoma

Cobimetinib [230]

Allosteric MEK

Melanoma,

RO5126766 [231]

Allosteric MEK

Solid tumor, multiple myeloma

SCH772984 [235]

ATP competitive ERK

KRAS-mutant lung cancer

VX11e [237]

ATP competitive ERK

BRAF-inhibitor progressed melanoma
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Table 8.

Author Manuscript

PTPs involved in the regulation of STAT3 signaling in carcinogenesis.
PTP

Target

PTPRT [243, 246]

STAT3

TC-PTP [261, 284]

EGFR, STAT3, JAK1, JAK3, Src

PTPRD [252]

STAT3

Types of cancer
Colon cancer, head and neck cancer
Breast cancer, skin cancer
Glioblastoma

SHP1 [267–270]

EGFR, JAK2, STAT3

Lymphoma, liver cancer, breast cancer, colon cancer

SHP2 [272]

EGFR, JAK2, STAT3

Liver cancer
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